Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.8M
-
Number of holders
-
122
-
Total 13F shares, excl. options
-
87.2M
-
Shares change
-
-2.03M
-
Total reported value, excl. options
-
$430M
-
Value change
-
-$8.69M
-
Put/Call ratio
-
0.68
-
Number of buys
-
63
-
Number of sells
-
-46
-
Price
-
$4.93
Significant Holders of ACELYRIN, Inc. - Common Stock (SLRN) as of Q3 2024
136 filings reported holding SLRN - ACELYRIN, Inc. - Common Stock as of Q3 2024.
ACELYRIN, Inc. - Common Stock (SLRN) has 122 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 87.2M shares
of 99.8M outstanding shares and own 87.43% of the company stock.
Largest 10 shareholders include T. Rowe Price Investment Management, Inc. (10.4M shares), AyurMaya Capital Management Company, LP (9.33M shares), CITADEL ADVISORS LLC (6.52M shares), BlackRock, Inc. (5.98M shares), MILLENNIUM MANAGEMENT LLC (5.49M shares), VANGUARD GROUP INC (4.07M shares), ORBIMED ADVISORS LLC (4M shares), venBio Partners LLC (3.85M shares), TYBOURNE CAPITAL MANAGEMENT (HK) LTD (2.91M shares), and GENERAL ATLANTIC, L.P. (2.89M shares).
This table shows the top 122 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.